Kymera Therapeutics and Kion Group see shifts in trading volume and analyst ratings

Kymera Therapeutics experienced a significant surge in trading volume, with 2,086,578 shares traded, marking a 185% increase from the previous session. The stock recently traded at $107.30. Analysts have provided various outlooks, including an overweight rating from Morgan Stanley with a $135.00 target and an outperform rating from Oppenheimer with a $125.00 target. The company holds a market capitalization of $8.99 billion.

Kion Group also saw fluctuations in trading activity, with approximately 17,120 shares traded during mid-day, a 30% decline from the prior session. The stock last traded at $11.5148. Recent analyst actions include an upgrade to overweight by Morgan Stanley and a downgrade to strong sell by Zacks Research. Kion Group reported quarterly revenue of $3.39 billion, exceeding analyst expectations, and maintains a market capitalization of $5.99 billion.